Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.53 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.53 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.53 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.53 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1825612 | 0.88 | GAA (0.54) | TAS2R14ALDH1A1PKMMEN1KMT2A | |
| SCHEMBL31236067 | 0.80 | TAS2R14 (0.61) | TAS2R14KDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL11358865 | 0.80 | TAS2R14 (0.61) | TAS2R14KDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL8415280 | 0.80 | TAS2R14 (0.61) | TAS2R14KDM4EGRIN2DGRIN3BGRIN1 | |
| Potassium Ion SCHEMBL11361356 | 0.80 | TAS2R14 (0.61) | TAS2R14KDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL11358861 | 0.80 | TAS2R14 (0.61) | TAS2R14KDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL11351333 | 0.80 | TAS2R14 (0.61) | TAS2R14KDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL11361353 | 0.78 | TAS2R14 (0.59) | TAS2R14KDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL11358859 | 0.78 | TAS2R14 (0.59) | TAS2R14KDM4EGRIN2DGRIN3BGRIN1 | |
| Potassium SCHEMBL11361366 | 0.78 | TAS2R14 (0.59) | TAS2R14KDM4EGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4367103-B1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20240376084-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2024-11-14 | — | — | US | disclosed |
| EP-4367103-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023280970-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-01-12 | — | — | WO | disclosed |
| US-10889555-B2 | Sulfonamide compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-20200405697-A1 | Antitumor Agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-24 | — | — | US | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| EP-2970215-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-8461134-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110172187-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| EP-0647137-B1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | UNIV CALIFORNIA (US) | 2008-08-13 | — | — | EP | disclosed |
| US-5912245-A | AMPA AND KAINATE ANTAGONISTS. | EGIS GYOGYSZERGYAR RT. (HU) | 1999-06-15 | — | — | US | disclosed |
| US-5622952-A | NERVOUS SYSTEM DISORDERS; ADMINISTERING 1,4-DIHYDROQUINOXALINE-2,3-DIONE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-22 | — | — | US | disclosed |
| US-5620979-A | TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0759910-A1 | ACID AMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | EGIS GYOGYSZERGYAR RT. (HU) | 1997-03-05 | — | — | EP | disclosed |
| US-5514680-A | ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE | THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| WO-1995031443-A1 | ACID AMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | EGIS Gyógyszergyár Rt. (HU) | 1995-11-23 | — | — | WO | disclosed |
| WO-1994000124-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | WEBER ECKARD (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | TAS2R14 539/4885KDM4E 1551/4885GRIN2D 4491/4885 |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | TAS2R14 539/4885KDM4E 1551/4885GRIN2D 4491/4885 |
| US-20110172187-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | TAS2R14 2386/4885KDM4E 2557/4885GRIN2D 4807/4885 |
| US-10889555-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | TAS2R14 539/4885KDM4E 1551/4885GRIN2D 4491/4885 |
| US-20240376084-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | SERPINB1, LTA, SERPINC1 | TAS2R14 4301/4885KDM4E 3942/4885GRIN2D 4864/4885 |
| US-20200405697-A1 | Antitumor Agent | HNRNPR, RRM2, RRM2B | TAS2R14 1622/4885KDM4E 2851/4885GRIN2D 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.